SCHEMBL29306397

SCHEMBL29306397

CC(C)CCCNC(=O)C1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.45
NAAA Q02083 1/20 0.44
MEN1 O00255 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP3A4 P08684 2/20 0.41
GNAI3 P08754 1/20 0.41
GNAO1 P09471 1/20 0.41
GNAI1 P63096 1/20 0.41
ALDH1A1 P00352 2/20 0.41
PIK3CD O00329 1/20 0.41
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP2D6 P10635 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
EPHX2 P34913 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24654177 0.91 HSD17B10 (0.43) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL29306398 0.88 HSD17B10 (0.54) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL17789630 0.85 NAAA (0.56) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL10137833 0.83 NAAA (0.63) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL10137843 0.82 HSD17B10 (0.49) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL28342798 0.81 NAAA (0.56) HSD17B10NAAAMEN1CYP2C19KMT2A
SCHEMBL25801598 0.81 HSD17B10 (0.48) HSD17B10NAAAMEN1CYP2C19KMT2A
SCHEMBL21206998 0.80 SMN1; SMN2 (0.46) HSD17B10SMN1; SMN2CYP2C19KMT2AALDH1A1
SCHEMBL10174280 0.79 NAAA (0.66) HSD17B10SMN1; SMN2NAAAMEN1CYP2C19
SCHEMBL29300398 0.78 HSD17B10 (0.46) HSD17B10NAAAMEN1CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ARES CAPITAL CORPORATION, AS AGENT 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226026-A1 BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PLTP, LNPK, PLIN3 HSD17B10 3145/4885SMN1; SMN2 1663/4885NAAA 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.